After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for DexCom Inc. (DXCM) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by +$5.87, or +6.91%, to $90.85. Volume reached 120,628 shares, with price reaching a high of $90.97 and a low of $90.74. Most recently, Yahoo Finance reported about the stock as it publicized that Dexcom G7 Launches in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System.
DXCM belongs to the Healthcare sector of the NASDAQ while operating in the Diagnostics & Research industry. At the end of the last regular session, the stock closed at $90.97 and fluctuated between $91.56 as its day high and $87.64 as its day low. The current market capitalization of DexCom Inc. is $36.41B. A total of 3.05 million shares were traded on the day, compared to an average of 2.55M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, DXCM has seen 0 BUY and 3 SELL insider trades, representing the acquisition of 0 and the disposition of 2,005 shares. Over the last 12 months, there were 39 BUYs and 157 SELLs from insiders. Insiders purchased 155,883 shares during that period but sold 122,845.
In the most recent transaction, Dolan Matthew Vincent sold 5 shares of DXCM for 81.63 per share on Sep 01. After the transaction, the SVP Corporate Strategy-Develop now owns 26,536 company shares. In a previous transaction on Aug 23, Pacelli Steven Robert sold 1,000 shares at 84.21 per share. DXCM shares that EVP Managing Director Dexcom V owns now total 137,700.
Among the insiders who sold shares, Pacelli Steven Robert disposed of 1,000 shares on Jul 25 at a per-share price of $83.07. This resulted in the EVP Managing Director Dexcom V holding 138,700 shares of DXCM after the transaction. In another insider transaction, Pacelli Steven Robert sold 1,000 shares at $72.55 per share on Jun 23. Company shares held by the EVP Managing Director Dexcom V now total 139,700.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for DXCM in the last 3 months, the mean price target is $99.80 with high estimates of $112.00 and low estimates of $83.00. In terms of 52-week highs and lows, DXCM has a high of $164.86 and a low of $66.89.
As of this writing, DXCM has an earnings estimate of $0.24 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of $0.27 per share and a lower estimate of $0.21.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. DXCM’s latest balance sheet shows that the firm has $2.73B in Cash & Short Term Investments as of fiscal 2021. There were $1.88B in debt and $720.80M in liabilities at the time. Its Book Value Per Share was $5.75, while its Total Shareholder’s Equity was $2.25B.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 18 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DXCM is Underweight with a score of 4.79. A total of 12 analysts rated the stock as Buy while 3 rated it as Overweight while 3 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.